Contact Us

CleanCap® FLuc mRNA (5moU) - (L-7202)

CleanCap® Firefly Luciferase mRNA (5-methoxyuridine)
In stock
Product SKU Unit Size Price Qty
L-7202-100 100 µg
L-7202-1000 1 mg
L-7202-5 5 x 1 mg



The FLuc mRNA expresses a luciferase protein, originally isolated from the firefly, Photinus pyralis. FLuc is commonly used in mammalian cell culture to measure both gene expression and cell viability. It emits bioluminescence in the presence of the substrate, luciferin.

This mRNA is capped using CleanCap® Reagent AG, TriLink's patented co-transciptional capping technology, which results in the naturally occurring Cap-1 structure with >95% capping efficiency. It is manufactured using TriLink’s CleanScript™ method*, polyadenylated, modified with 5-methoxyuridine, and optimized for mammalian systems. It mimics a fully processed mature mRNA.

CleanCap® Reagent AG produces a base-modified Cap-1 mRNA, which shows superior in vivo activity compared to Cap-0 mRNA produced by legacy capping methods such as mCap or anti-reverse cap analog (ARCA).

5-methoxyuridine is a modified uridine that can reduce immunogenic response and enhance translational efficiency of mRNAs. These properties can result in safer mRNA and increased protein expression.

CleanScript™ method is TriLink’s proprietary in vitro transcription process that is optimized to minimize dsRNA formation and increase mRNA activity in vivo.

*Starting April 30th, 2024

Product details
Catalog No L-7202
Purity Passes Agarose Gel Mobility
Length 1922 nucleotides
Base Composition Fully substituted with 5-Methoxy-U
Concentration 1.0 mg/mL
Buffer 1 mM Sodium Citrate pH 6.4
Conversion Factor 40 µg/OD260
Recommended Storage At or below -40°C
Application Reporter Genes
Cap AG Start, Cap 1, CleanCap
Other Name(s) CleanCap® Firefly Luciferase mRNA (5-methoxyuridine)
Technical documents

L-7202 Safety Data Sheet

L-7202 Product Insert

CleanCap FLuc ORF Sequence

Products faqs

Ask an Expert

Certificate of analysis

CoA search tool

Intellectual property

CleanCap capping technology For Research Use Only. Not for use in humans. Not for use in diagnostic or therapeutic purposes. For additional licensing restrictions, please see the license agreement at Patents and patent pending, see

Products are for research use only, not for use in diagnostic or therapeutic procedures or for use in humans. Products are not for resale without express written permission from TriLink No license under any patent or other intellectual property right of TriLink or its licensors is granted or implied by the purchase unless otherwise provided in writing.

TriLink does not warrant that the use or sale of the products delivered hereunder will not infringe the claims of any United States or other patents or patents pending covering the use of the product alone or in combination with other products or in the operation of any process. All and any use of TriLink product is the purchaser's sole responsibility.

  1. Zinger, A;Cvetkovic, C;Sushnitha, M;Naoi, T;Baudo, G;Anderson, M;Shetty, A;Basu, N;Covello, J;Tasciotti, E;Amit, M;Xie, T;Taraballi, F;Krencik, R; . Humanized Biomimetic Nanovesicles for Neuron Targeting
  2. Herrera, M;Kim, J;Eygeris, Y;Jozic, A;Sahay, G; . Illuminating endosomal escape of polymorphic lipid nanoparticles that boost mRNA delivery
  3. Duran-Mota, JA;Yani, JQ;Almquist, BD;Borr . Polyplex-Loaded Hydrogels for Local Gene Delivery to Human Dermal Fibroblasts
  4. Jansig, E;Geissler, S;Rieckmann, V;Kuenemund, A;Hietel, B;Schenk, M;Wussow, S;Kreideweiss, P;Panzner, S;Reinsch, C;Cynis, H; . Viromers as carriers for mRNA-mediated expression of therapeutic molecules under inflammatory conditions
  5. Lacroix, C;Humanes, A;Coiffier, C;Gigmes, D;Verrier, B;Trimaille, T; . Polylactide-Based Reactive Micelles as a Robust Platform for mRNA Delivery
  6. Ryals, RC;Patel, S;Acosta, C;McKinney, M;Pennesi, ME;Sahay, G; . The effects of PEGylation on LNP based mRNA delivery to the eye
  7. Kim, J;Jozic, A;Sahay, G; . Naturally Derived Membrane Lipids Impact Nanoparticle-Based Messenger RNA Delivery
  8. Gambari, R;Gasparello, J;Fabbri, E;Borgatti, M;Tamanini, A;Finotti, A; . Peptide Nucleic Acids for MicroRNA Targeting
  9. Herskovitz, J;Hasan, M;Patel, M;Blomberg, WR;Cohen, JD;Machhi, J;Shahjin, F;Mosley, RL;McMillan, J;Kevadiya, BD;Gendelman, HE; . CRISPR-Cas9 Mediated Exonic Disruption for HIV-1 Elimination
  10. Cui, L;Hunter, MR;Sonzini, S;Pereira, S;Romanelli, SM;Liu, K;Li, W;Liang, L;Yang, B;Mahmoudi, N;Desai, AS; . Mechanistic Studies of an Automated Lipid Nanoparticle Reveal Critical Pharmaceutical Properties Associated with Enhanced mRNA Functional Delivery In Vitro and In Vivo
  11. Dilliard, SA;Cheng, Q;Siegwart, DJ; . On the mechanism of tissue-specific mRNA delivery by selective organ targeting nanoparticles
  12. Rui, Y;Wilson, DR;Tzeng, SY;Yamagata, HM;Sudhakar, D;Conge, M;Berlinicke, CA;Zack, DJ;Tuesca, A;Green, JJ; . High-throughput and high-content bioassay enables tuning of polyester nanoparticles for cellular uptake, endosomal escape, and systemic in vivo delivery of mRNA
  13. Markova, N;Cairns, S;Jankevics-Jones, H;Kaszuba, M;Caputo, F;Parot, J; . Biophysical Characterization of Viral and Lipid-Based Vectors for Vaccines and Therapeutics with Light Scattering and Calorimetric Techniques
  14. Dyson, J;Abbasi, F;Varadkar, P;McCright, B; . Growth arrest of PPP2R5C and PPP2R5D double knockout mice indicates a genetic interaction and conserved function for these PP2A B subunits
Show more